Evidence map›Paper›PMID 36361608›Full record

ArticleInternational journal of molecular sciences2022

Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome.

Ariadna Anunciación-Llunell, Cándido Muñoz, Dirk Roggenbuck, Stefano Frasca, Josep Pardos-Gea, Enrique Esteve-Valverde, Jaume Alijotas-Reig, Francesc Miró-Mur

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Antiphospholipid Syndrome in Pregnancy: New and Old Pathogenetic Mechanisms.International journal of molecular sciences · 2023
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Ariadna Anunciación-LlunellSystemic Autoimmune Diseases Research Unit, Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Catalonia, Spain.
Cándido MuñozCentre for Rheumatology Research, University College of London, London WC1E 6JF, UK.
Dirk RoggenbuckFaculty of Health Sciences Brandenburg, Brandenburg University of Technology Cottbus-Senftenberg, 01968 Senftenberg, Germany.
Stefano FrascaGA Generic Assays GmbH, 15827 Dahlewitz, Germany.
Josep Pardos-GeaSystemic Autoimmune Diseases Research Unit, Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Catalonia, Spain.
Enrique Esteve-ValverdeSystemic Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitari Parc Taulí, 08208 Sabadell, Catalonia, Spain.ORCID 0000-0002-1403-8419
Jaume Alijotas-ReigSystemic Autoimmune Diseases Research Unit, Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Catalonia, Spain.
Francesc Miró-MurSystemic Autoimmune Diseases Research Unit, Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Catalonia, Spain.ORCID 0000-0003-3936-2693
Vall d'Hebron Institut de Recerca · ESGeneric Assays (Germany) · DEDeleted InstitutionUniversitat Autònoma de Barcelona · ESUniversity College London · GB

Funding

Gravida Fertilitat Avançada GRA-JAR-2021Ona Futura Foundation ONA-JAR-2021
6 · The paper itself

Abstract

Antiphospholipid syndrome (APS) is a systemic autoimmune condition characterised by the presence of antiphospholipid antibodies (aPL) associated with vascular thrombosis and/or pregnancy complications. In a cohort of 74 yet diagnosed APS individuals fulfilling Sydney laboratory criteria (twice positive for lupus anticoagulant, anticardiolipin, aCL, and/or anti-β2glycoprotein I, aβ2GPI), 33 out of 74 were obstetric APS (OAPS) and 41 thrombotic APS (TAPS) patients. 39% of TAPS patients were women. Although aPL detection was persistent, we observed an oscillatory aPL positivity in 56.7% and a transient seroconversion in 32.4% of APS patients at enrolment. Thus, we tested their sera in a line immunoassay that simultaneously detected IgG or IgM for criteria (aCL and aβ2GPI) and non-criteria (anti-phosphatidylserine, aPS; anti-phosphatidic acid, aPA; anti-phosphatidylinositol, aPI; anti-annexin 5, aA5; anti-prothrombin, aPT; anti-phosphatidylethanolamine; anti-phosphatidylglycerol, and anti-phosphatidylcholine) aPL. OAPS and TAPS patients displayed different but overlapping clusters based on their aPL reactivities. Specifically, while OAPS patients showed higher aPA, aPS, aA5, aβ2GPI and aPT IgM levels than TAPS patients, the latter displayed higher reactivity in aCL, aPI and aA5 IgG. Eventually, with a cut-off of the 99

Indexed as

Antiphospholipid SyndromeThrombosisAntibodies, Antiphospholipidbeta 2-Glycoprotein IDimapritFemaleHumansImmunoglobulin GImmunoglobulin MMalePregnancyAntibodies, AntiphospholipidAPTbeta 2-Glycoprotein IDimapritImmunoglobulin GImmunoglobulin Mantiphospholipid antibodiesline Immunoassaynon-criteria antiphospholipid antibodyobstetric antiphospholipid syndromethrombotic antiphospholipid syndrome

Identifiers

PMID36361608
PMCPMC9658219
OpenAlexW4307262618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.